This inventor holds 6 USPTO granted patents and 7 published patent applications and 2 EPO patents. Top assignees: National Institute of Health and Medical Research, Centre National De La Recherche Scientifique, Université Paris Descartes. Active years: 2015-2025.
Location History:
- Paris Cedex 14, FR (2015)
- Paris, FR (2017 - 2021)
Company Filing History:
6 out of 1,853 
3 out of 5,383 
3 out of 132 
Years Active: 2015-2025
Title: The Innovative Contributions of Roberto Mallone
Introduction
Roberto Mallone is a prominent inventor based in Paris, France. He has made significant contributions to the field of medical research, particularly in the diagnosis and treatment of type 1 diabetes. With a total of 6 patents to his name, Mallone's work has garnered attention for its innovative approaches to understanding autoimmune diseases.
Latest Patents
Mallone's latest patents include groundbreaking research on antigenic peptides. One notable patent is focused on "Antigenic Peptides Deriving from Secretogranin V and Uses Thereof for the Diagnosis and Treatment of Type 1 Diabetes." Another significant patent involves "Antigenic Peptides Deriving from Urocortin 3 and Uses Thereof for the Diagnosis and Treatment of Type 1 Diabetes." His research highlights the role of inflammatory cytokines in increasing β-cell peptide presentation, which is crucial for developing new therapeutic strategies for type 1 diabetes.
Career Highlights
Throughout his career, Mallone has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université Paris Descartes. His research has not only advanced scientific understanding but has also paved the way for potential clinical applications in diabetes treatment.
Collaborations
Mallone has collaborated with notable colleagues, including Georgia Afonso and Slobodan Culina. These partnerships have enriched his research and contributed to the success of his innovative projects.
Conclusion
Roberto Mallone's contributions to medical research, particularly in the field of type 1 diabetes, demonstrate his commitment to innovation and scientific advancement. His patents reflect a deep understanding of autoimmune mechanisms and hold promise for future therapeutic developments.